Результаты исследований: Научные публикации в периодических изданиях › обзорная статья › Рецензирование
Tick-borne encephalitis in Europe and Russia : Review of pathogenesis, clinical features, therapy, and vaccines. / Ruzek, Daniel; Avšič Županc, Tatjana; Borde, Johannes и др.
в: Antiviral Research, Том 164, 04.2019, стр. 23-51.Результаты исследований: Научные публикации в периодических изданиях › обзорная статья › Рецензирование
}
TY - JOUR
T1 - Tick-borne encephalitis in Europe and Russia
T2 - Review of pathogenesis, clinical features, therapy, and vaccines
AU - Ruzek, Daniel
AU - Avšič Županc, Tatjana
AU - Borde, Johannes
AU - Chrdle, Ales
AU - Eyer, Ludek
AU - Karganova, Galina
AU - Kholodilov, Ivan
AU - Knap, Nataša
AU - Kozlovskaya, Liubov
AU - Matveev, Andrey
AU - Miller, Andrew D.
AU - Osolodkin, Dmitry I.
AU - Överby, Anna K.
AU - Tikunova, Nina
AU - Tkachev, Sergey
AU - Zajkowska, Joanna
N1 - Funding Information: The authors acknowledge financial support from: Funding Information: • The Russian Scientific Foundation (project #16-14-00083) to NT and AM,• Ministry of Education and Science of the Russian Federation (project 0309-2016-0002) to NT and ST,• Ministry of Health of the Czech Republic (grant No. 16-34238A) (to DR and LE), by Project “FIT” (Pharmacology, Immunotherapy, nanoToxicology; CZ.02.1.01/0.0/0.0/15_003/0000495), which was funded by the European Regional Development Fund (to ADM and DR),• The Laboratory for Molecular Medicine Sweden (MIMS), the Swedish Research Council (VR; 2017-02438), the Swedish Foundation for Strategic Research (SSF; FFL12-0089) to AKÖ,• The Ministry of Higher Education, Science and Sport of Slovenia (grant no. P3-0083) to TAŽ and NK. Funding Information: • Ministry of Health of the Czech Republic (grant No. 16-34238A ) (to DR and LE), by Project “ FIT ” (Pharmacology, Immunotherapy, nanoToxicology; CZ.02.1.01/0.0/0.0/15_003/0000495 ), which was funded by the European Regional Development Fund (to ADM and DR), Publisher Copyright: © 2019 Elsevier B.V. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/4
Y1 - 2019/4
N2 - Tick-borne encephalitis (TBE) is an illness caused by tick-borne encephalitis virus (TBEV) infection which is often limited to a febrile illness, but may lead to very aggressive downstream neurological manifestations. The disease is prevalent in forested areas of Europe and northeastern Asia, and is typically caused by infection involving one of three TBEV subtypes, namely the European (TBEV-Eu), the Siberian (TBEV-Sib), or the Far Eastern (TBEV-FE) subtypes. In addition to the three main TBEV subtypes, two other subtypes; i.e., the Baikalian (TBEV-Bkl) and the Himalayan subtype (TBEV-Him), have been described recently. In Europe, TBEV-Eu infection usually results in only mild TBE associated with a mortality rate of <2%. TBEV-Sib infection also results in a generally mild TBE associated with a non-paralytic febrile form of encephalitis, although there is a tendency towards persistent TBE caused by chronic viral infection. TBE-FE infection is considered to induce the most severe forms of TBE. Importantly though, viral subtype is not the sole determinant of TBE severity; both mild and severe cases of TBE are in fact associated with infection by any of the subtypes. In keeping with this observation, the overall TBE mortality rate in Russia is ∼2%, in spite of the fact that TBEV-Sib and TBEV-FE subtypes appear to be inducers of more severe TBE than TBEV-Eu. On the other hand, TBEV-Sib and TBEV-FE subtype infections in Russia are associated with essentially unique forms of TBE rarely seen elsewhere if at all, such as the hemorrhagic and chronic (progressive) forms of the disease. For post-exposure prophylaxis and TBE treatment in Russia and Kazakhstan, a specific anti-TBEV immunoglobulin is currently used with well-documented efficacy, but the use of specific TBEV immunoglobulins has been discontinued in Europe due to concerns regarding antibody-enhanced disease in naïve individuals. Therefore, new treatments are essential. This review summarizes available data on the pathogenesis and clinical features of TBE, plus different vaccine preparations available in Europe and Russia. In addition, new treatment possibilities, including small molecule drugs and experimental immunotherapies are reviewed. The authors caution that their descriptions of approved or experimental therapies should not be considered to be recommendations for patient care.
AB - Tick-borne encephalitis (TBE) is an illness caused by tick-borne encephalitis virus (TBEV) infection which is often limited to a febrile illness, but may lead to very aggressive downstream neurological manifestations. The disease is prevalent in forested areas of Europe and northeastern Asia, and is typically caused by infection involving one of three TBEV subtypes, namely the European (TBEV-Eu), the Siberian (TBEV-Sib), or the Far Eastern (TBEV-FE) subtypes. In addition to the three main TBEV subtypes, two other subtypes; i.e., the Baikalian (TBEV-Bkl) and the Himalayan subtype (TBEV-Him), have been described recently. In Europe, TBEV-Eu infection usually results in only mild TBE associated with a mortality rate of <2%. TBEV-Sib infection also results in a generally mild TBE associated with a non-paralytic febrile form of encephalitis, although there is a tendency towards persistent TBE caused by chronic viral infection. TBE-FE infection is considered to induce the most severe forms of TBE. Importantly though, viral subtype is not the sole determinant of TBE severity; both mild and severe cases of TBE are in fact associated with infection by any of the subtypes. In keeping with this observation, the overall TBE mortality rate in Russia is ∼2%, in spite of the fact that TBEV-Sib and TBEV-FE subtypes appear to be inducers of more severe TBE than TBEV-Eu. On the other hand, TBEV-Sib and TBEV-FE subtype infections in Russia are associated with essentially unique forms of TBE rarely seen elsewhere if at all, such as the hemorrhagic and chronic (progressive) forms of the disease. For post-exposure prophylaxis and TBE treatment in Russia and Kazakhstan, a specific anti-TBEV immunoglobulin is currently used with well-documented efficacy, but the use of specific TBEV immunoglobulins has been discontinued in Europe due to concerns regarding antibody-enhanced disease in naïve individuals. Therefore, new treatments are essential. This review summarizes available data on the pathogenesis and clinical features of TBE, plus different vaccine preparations available in Europe and Russia. In addition, new treatment possibilities, including small molecule drugs and experimental immunotherapies are reviewed. The authors caution that their descriptions of approved or experimental therapies should not be considered to be recommendations for patient care.
KW - Antiviral therapy
KW - Clinical course
KW - Pathogenesis
KW - Tick-borne encephalitis
KW - Tick-borne encephalitis virus
KW - Vaccines
KW - Encephalitis Viruses, Tick-Borne/immunology
KW - Europe
KW - Humans
KW - Encephalitis, Tick-Borne/drug therapy
KW - Phylogeny
KW - Russia
KW - Ticks/virology
KW - Animals
KW - Antiviral Agents/therapeutic use
KW - Viral Vaccines/immunology
KW - Mice
UR - http://www.scopus.com/inward/record.url?scp=85061389498&partnerID=8YFLogxK
U2 - 10.1016/j.antiviral.2019.01.014
DO - 10.1016/j.antiviral.2019.01.014
M3 - Review article
C2 - 30710567
AN - SCOPUS:85061389498
VL - 164
SP - 23
EP - 51
JO - Antiviral Research
JF - Antiviral Research
SN - 0166-3542
ER -
ID: 27699366